Y0001173
Filgrastim
European Pharmacopoeia (EP) Reference Standard
Bejelentkezésa Szervezeti és Szerződéses árazás megtekintéséhez
Összes fotó(1)
About This Item
Javasolt termékek
grade
pharmaceutical primary standard
API-család
filgrastim
gyártó/kereskedő neve
EDQM
alkalmazás(ok)
pharmaceutical (small molecule)
Formátum
neat
tárolási hőmérséklet
−70°C
Looking for similar products? Látogasson el ide Útmutató a termékösszehasonlításhoz
Általános leírás
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Alkalmazás
Filgrastim EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Kiszerelés
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Egyéb megjegyzések
Sales restrictions may apply.
kapcsolódó termék
Product No.
Leírás
Árazás
Tárolási osztály kódja
11 - Combustible Solids
WGK
WGK 3
Lobbanási pont (F)
Not applicable
Lobbanási pont (C)
Not applicable
Válasszon a legfrissebb verziók közül:
Analitikai tanúsítványok (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumentumok section.
Ha segítségre van szüksége, lépjen velünk kapcsolatba Vevőszolgálat
Már rendelkezik ezzel a termékkel?
Az Ön által nemrégiben megvásárolt termékekre vonatkozó dokumentumokat a Dokumentumtárban találja.
Az ügyfelek ezeket is megtekintették
Maria Moroni et al.
International journal of radiation oncology, biology, physics, 86(5), 986-992 (2013-07-13)
We are characterizing the Gottingen minipig as an additional large animal model for advanced drug testing for the acute radiation syndrome (ARS) to enhance the discovery and development of novel radiation countermeasures. Among the advantages provided by this model, the
Arash Naeim et al.
BMC cancer, 13, 11-11 (2013-01-10)
Myelosuppressive chemotherapy can lead to dose-limiting febrile neutropenia. Prophylactic use of recombinant human G-CSF such as daily filgrastim and once-per-cycle pegfilgrastim may reduce the incidence of febrile neutropenia. This comparative study examined the effect of pegfilgrastim versus daily filgrastim on
Ruben Niesvizky et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 19(6), 1534-1546 (2013-01-30)
This phase II study evaluated bortezomib-based secondary induction and stem cell mobilization in 38 transplant-eligible patients with myeloma who had an incomplete and stalled response to, or had relapsed after, previous immunomodulatory drug-based induction. Patients received up to six 21-day
Pierre Rofail et al.
Expert review of pharmacoeconomics & outcomes research, 12(6), 699-709 (2012-12-21)
For oncology patients, febrile neutropenia (FN) can be a serious and costly toxicity of chemotherapy, often forcing a reduction in chemotherapy dose intensity and/or duration. Several therapeutic agents are used to reduce the occurrence of neutropenic episodes: granulocyte colony-stimulating factors
L M Rozhdestvenskiĭ et al.
Radiatsionnaia biologiia, radioecologiia, 52(5), 503-509 (2012-12-12)
In the experiments on F1 (CBA x C57BL) and BALB mice irradiated by 137Cs gamma-rays, preparations of unglycosilated G-SCF such as Neupogen and their domestic analogs Leucostim and Neupomax were investigated. The tests such as 9-day bone marrow cellularity (BMC)
Tudóscsoportunk valamennyi kutatási területen rendelkezik tapasztalattal, beleértve az élettudományt, az anyagtudományt, a kémiai szintézist, a kromatográfiát, az analitikát és még sok más területet.
Lépjen kapcsolatba a szaktanácsadással